Skip to main content
Clinical Trials/CTRI/2017/05/008545
CTRI/2017/05/008545
Recruiting
Phase 3

Single blind randomized controlled clinical study to evaluate the efficacy and safety of shivagutika in dyslipidemia

Rajiv Gandhi University of Health Sciences0 sites60 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: E038- Other specified hypothyroidism
Sponsor
Rajiv Gandhi University of Health Sciences
Enrollment
60
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients fulfilling the diagnostic criteria.
  • 2\.Lipid profile, showing any one or more of the following criteria.
  • Serum cholesterol \>200 mg/dl
  • Serum Triglycerides \>150 mg/dl
  • Serum LDL \>130 mg/dl
  • Serum VLDL \>40 mg/dl
  • Serum HDL \<40 for male \<30 for female
  • Ratio of HDL to Cholesterol \>4\.5
  • Apolipoprotien B \>125mg/dl
  • 3\.Both fresh and treated cases will be included (Flush out period of 7 days is maintained for treated cases)

Exclusion Criteria

  • 1\.Patients having history of serious cardiac disorders like myocardial infarction, cardiac failure, etc.
  • 2\.Patients having any major illness, insulin dependent diabetes mellitus, Type II diabetes mellitus that is poorly controlled
  • 3\.Patients having a history of untreated thyroid disorder
  • 4\.Hyperlipidemia due to drugs (e.g., glucocorticoids)
  • 5\.Pregnant females and lactating mothers
  • 6\.Renal insufficiency

Outcomes

Primary Outcomes

Not specified

Similar Trials